Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis - Wikidata - awgldk - TriplyDB

Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis

Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis

http://www.wikidata.org/entity/Q33947318

about

The Current and Future Treatment of Brain Metastases Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets Biology of MET: a double life between normal tissue repair and tumor progression Brain Radiotherapy plus Concurrent Temozolomide versus Radiotherapy Alone for Patients with Brain Metastases: A Meta-Analysis.Current approaches to the treatment of metastatic brain tumours.Epidermal Growth Factor Receptor Mutational Status and Brain Metastases in Non-Small-Cell Lung Cancer A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry Exosomal proteins as potential diagnostic markers in advanced non-small cell lung carcinoma.Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity.FGFR2 is amplified in the NCI-H716 colorectal cancer cell line and is required for growth and survival.MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody.The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma.Identification of Caspase Cleavage Sites in KSHV Latency-Associated Nuclear Antigen and Their Effects on Caspase-Related Host Defense Responses.Molecular Markers with Predictive and Prognostic Relevance in Lung Cancer Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy.Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?Tyrosine kinase inhibitors in lung cancer.Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer.Towards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions.MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: A case report and review of the literature.Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2.Targeting genomic alterations in squamous cell lung cancer.A nuclear-directed human pancreatic ribonuclease (PE5) targets the metabolic phenotype of cancer cells.Quantitative Secretomic Analysis Identifies Extracellular Protein Factors That Modulate the Metastatic Phenotype of Non-Small Cell Lung Cancer.MicroRNAs as therapeutic targets in chemoresistance.Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker.Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive.MET: a promising anticancer therapeutic target.EGFR mutation status in brain metastases of non-small cell lung carcinoma.Multispectral imaging: a review of its technical aspects and applications in anatomic pathology.Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer.Molecular determinants of lung cancer metastasis to the central nervous system.cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance.

P2860

Q26744019-EDA22BDA-AA2E-4DCC-8A2F-27EE5B21F058 Q26744339-FC4EFE7A-F5C0-41E9-819A-17E74603643B Q26823903-75F8AE46-A52D-485A-B9B3-CABAF9BBC467 Q26852215-87116743-0386-4E74-A127-FC95DCA69DCA Q27853202-A24E88E1-0542-4A18-9C6B-F888DF72BACB Q28081193-08A8DC8D-E481-4C02-9F16-6B731A4495A2 Q28085247-5DA525BC-A8D5-4B3E-BEB5-B368F1CB469C Q33430404-9D81D896-46B9-400B-89A3-554F63E0C421 Q33696559-E7B78EC2-9449-4044-A5E9-C8D36B984980 Q33859503-6AE0ECCA-2B0B-4C61-87A5-52F88FF402A8 Q34405695-6C7E54D2-FEFC-477E-8D0A-135CDBCF6D02 Q35143602-900928CF-2E96-42BB-9199-939B37B93469 Q35153559-9224D5DB-030F-41C4-88B3-94237260230C Q35195738-B5F0D24C-134D-4375-AB31-D99B912CFC48 Q35208173-63DF6213-9051-433B-8EE1-1FC8FA419B2B Q35612939-8DDF66C2-0ECE-4D7D-86B0-7EFBDA95B978 Q35636713-C1AA86F7-A5A1-40EF-A7F7-69FA13210243 Q35720026-1B3EC45F-9DE2-4EF2-A982-C228A4D3D6EC Q35763239-2E620D1D-9618-4BC1-9983-419D91D3464F Q35882137-D947FDEA-7A96-4D56-A1B9-CBD1CE3B0B13 Q35896530-700F344B-353C-4D07-9B4D-AF985C992635 Q35908430-03009D05-B8DB-4D85-9932-6C5CA4AEF016 Q36173303-8CBB6DD5-973C-4C15-99D7-A8C59A85574F Q36264188-7ABE9901-46DA-4A6E-AAFD-9E25DB556236 Q36265149-326EFD37-A4A6-4DC5-A28D-FF7A394C9095 Q36826056-DEA703C3-1CB1-4744-A57C-BD7C996A5F97 Q36884275-6C197E8F-0CA8-4AAC-A993-A7AE08A090BD Q37068767-DD38737B-3EE0-46DE-9169-0231B08B70DC Q37109747-E75D1742-1EDF-4510-8664-1ECA8781F110 Q37210782-6CD3152E-2186-4178-B65B-8CF093F28121 Q37381107-0AB525B6-C289-4A70-A26A-F49E0A1F43CE Q37392703-14807521-ED45-4AED-B14A-F3E1B0622A3E Q37702041-E498A40D-43B2-459C-981D-A62113CC72F6 Q37894095-EE208535-38F8-4F4B-8C32-C036420439B4 Q38008247-BEFC93C2-EAB7-4044-8DA9-3A44388981C9 Q38053963-5A67AD3E-EF08-49E9-9EF3-015355C10A9A Q38152999-2BCA74EC-6B1A-4523-BE8C-A8DE741C78A7 Q38245669-F170F040-132A-4B17-BB23-6EFB773C4299 Q38390049-A04A73A4-3770-4057-BC07-EF820068582F Q38393333-7588209B-4722-4300-A099-CD2450E15B7F

P2860

Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis

http://www.wikidata.org/entity/Q33947318

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Met activation in non-small ce ...... evelopment of brain metastasis

@ast

Met activation in non-small ce ...... evelopment of brain metastasis

@en

type

label

Met activation in non-small ce ...... evelopment of brain metastasis

@ast

Met activation in non-small ce ...... evelopment of brain metastasis

@en

prefLabel

Met activation in non-small ce ...... evelopment of brain metastasis

@ast

Met activation in non-small ce ...... evelopment of brain metastasis

@en

P1433

Q33947318-E0EDECCD-9F6E-4C58-919A-4138438C5F1D

P1476

Q33947318-0F7B56E3-84B7-49BE-8F9D-63F98828EC99

P2093

Q33947318-2DACBE5E-9667-44E7-B1A1-BB3C97F819AC

Q33947318-3EB4840A-B7C2-4543-9271-3CEBB1B62EDB

Q33947318-456A1896-8110-4B69-80AA-BCE06447D37C

Q33947318-45B17BB3-B0D1-407A-905A-C999B2A08B39

Q33947318-496A9F13-00B7-4196-BF7D-759F08EDCC60

Q33947318-4CFC4070-A767-478D-9069-F50C6668CF76

Q33947318-5D56CA4A-D45B-48A5-822D-D8A5BC8E538E

Q33947318-5F37276B-786D-48C7-8962-929CAE421EF2

Q33947318-6540E015-4351-4292-97C4-D7B70CE5FFCC

Q33947318-66B11053-91AF-4D60-8658-00F707606D64

P2860

Q33947318-03AA485C-1796-4537-B934-6924D44A51A5

Q33947318-0BD21DB1-58C5-4255-98F2-8C601FA85C72

Q33947318-0D51F6C6-F36E-46B3-97E5-007E55A9194B

Q33947318-15C45C81-5BCB-4615-882D-4BA68411CF49

Q33947318-2308874A-041F-4CF1-951B-E8C723CB0815

Q33947318-289A59DA-EBAE-4C3E-A8F7-7F9A7DE5FD3E

Q33947318-2D1FD019-9C9A-4901-84AF-B43C4F926A05

Q33947318-324D1018-1F44-47D5-8496-98F1B9E05A38

Q33947318-3B01E87F-CC18-442C-AF8F-C39D0B07A7BD

Q33947318-44658EAD-DBFD-4032-AEE5-1E50985FB63C

P304

Q33947318-0B82A3F9-327B-4F04-A976-2F6AC66E9C1D

P31

Q33947318-0EB3D980-646D-43CD-A604-024A897D2C30

P356

Q33947318-5C713C86-3BE8-4CDB-8707-57CB2A461DC4

P407

Q33947318-68EA9AB5-9355-435E-9249-2788530747C1

P433

Q33947318-769686CC-9128-4528-82D7-71524F2D2D38

P478

Q33947318-B81990DC-09DF-4EB9-8E04-965E6F8B481B

P50

Q33947318-E79847FD-4E57-4B09-A4C2-AD9A6EA88C77

P577

Q33947318-D14E6B70-33BD-4ABC-83AB-33D6FC5C06D8

P5875

Q33947318-20C87A03-4A8B-4E46-8A2E-9535E6CD48EF

P698

Q33947318-7A9C40D9-3E9A-485C-8515-18D10E4CBC74

P932

Q33947318-2DA6D17A-67A6-472F-925D-2DFF98815020

P356

AJPATH.2010.090863

P1433

The American Journal of Pathology

P1476

Met activation in non-small ce ...... evelopment of brain metastasis

@en

P2093

Adi F Gazdar

http://www.w3.org/2001/XMLSchema#string

Azra H Ligon

http://www.w3.org/2001/XMLSchema#string

Bart Lutterbach

http://www.w3.org/2001/XMLSchema#string

Beow Y Yeap

http://www.w3.org/2001/XMLSchema#string

Bo-Sheng Pan

http://www.w3.org/2001/XMLSchema#string

Christopher Ware

http://www.w3.org/2001/XMLSchema#string

Dyane Bailey

http://www.w3.org/2001/XMLSchema#string

Elisa Benedettini

http://www.w3.org/2001/XMLSchema#string

Giulio Draetta

http://www.w3.org/2001/XMLSchema#string

John D Minna

http://www.w3.org/2001/XMLSchema#string

P2860

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Met, metastasis, motility and more

Invasive growth: a MET-driven genetic programme for cancer and stem cells

A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.

P304

415-423

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2353/AJPATH.2010.090863

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

177

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-05-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44617700

http://www.w3.org/2001/XMLSchema#string

P698

20489150

http://www.w3.org/2001/XMLSchema#string

P932

2893683

http://www.w3.org/2001/XMLSchema#string